All In MedTech

Device Trial Radar · NCT03421561

ILLUMENATE Pivotal Post-Approval Study (PAS)

ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon Pivotal Post-Approval Study

Last checked: Nov 19, 2026Latest source record: Feb 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Jun 18, 2013

Primary completion

Dec 8, 2017

Study completion Oct 6, 2020

Sponsor

Lead sponsor
Spectranetics CorporationNot on our public-company list
Sponsor type
Industry
First posted
Feb 5, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ILLUMENATE Pivotal PAS is a continued follow-up study which will include 300 subjects from forty-three (43) sites across the United States and Austria previously enrolled in the ILLUMENATE Pivotal pre-market study to evaluate the Stellarex DCB compared to the PTA control device for the treatment of de-novo or post-PTA occluded/stenotic or reoccluded/restenotic (except for in-stent) SFA and/or popliteal arteries.

Conditions

  • Peripheral Artery Disease

Interventions

  • Stellarex 0.035" OTW Drug-coated Angioplasty BalloonDevice

    The Stellarex 0.035" OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.

  • EverCross™ 0.035 PTA Balloon CatheterDevice

    The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Target Vessel Patency at 24 Months Post-procedureTime frame: 24 months post-procedure
  2. Number of Participants With Freedom From Device and Procedure Related Death Through 30 Days Post-procedure and Freedom From Target Limb Major Amputation and Clinically-driven Target Lesion Revascularization Through 24 Months Post-procedureTime frame: 24 months post-procedure

Locations

41 sites in 2 countries. Site status is shown where the registry gives one.

  • Yuma Regional Medical Center

    Yuma, Arizona

  • Mission Cardiovascular Research Institute

    Fremont, California

  • Good Samaritan Hospital - Los Angeles

    Los Angeles, California

38 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.